Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow margin | 21.2% | 24.1% | 24.0% | 19.7% | 14.9% | 26.8% | 24.8% | 19.4% | 8.3% | 20.8% | 16.5% | 2.2% | 8.0% | 8.7% | 5.6% | 2.1% | 8.2% | 10.1% | 16.3% | 14.3% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Free Cash Flow margin is 13.2%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Free Cash Flow margin for AstraZeneca PLC have been 13.6% over the past three years, and 12.0% over the past five years.
As of today, AstraZeneca PLC's Free Cash Flow margin is 13.2%, which is lower than industry median of 19.1%. It indicates that AstraZeneca PLC's Free Cash Flow margin is Bad.